114 related articles for article (PubMed ID: 26370036)
1. Disease activity-guided TNF inhibitor dose reduction was noninferior to continuing TNF inhibitors for RA flares.
Ramirez-Lafita F
Ann Intern Med; 2015 Sep; 163(6):JC9. PubMed ID: 26370036
[No Abstract] [Full Text] [Related]
2. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
[TBL] [Abstract][Full Text] [Related]
3. [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].
MMW Fortschr Med; 2003 Oct; 145(41):46. PubMed ID: 14655484
[No Abstract] [Full Text] [Related]
4. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
Nasonov EL
Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
[No Abstract] [Full Text] [Related]
7. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
8. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
[TBL] [Abstract][Full Text] [Related]
9. Two RA drugs better than one.
Health News; 2004 May; 10(5):10. PubMed ID: 15132111
[No Abstract] [Full Text] [Related]
10. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
11. Etanercept tapering in rheumatoid arthritis.
Graudal N; Jürgens G
N Engl J Med; 2015 Jan; 372(5):489. PubMed ID: 25629752
[No Abstract] [Full Text] [Related]
12. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
13. Nonserious infections: should there be cause for serious concerns?
Dao KH; Herbert M; Habal N; Cush JJ
Rheum Dis Clin North Am; 2012 Nov; 38(4):707-25. PubMed ID: 23137578
[TBL] [Abstract][Full Text] [Related]
14. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune hepatitis triggered by adalimumab and allergic reactions after various anti-TNFα therapy agents in a patient with rheumatoid arthritis.
Petríková J; Jarčuška P; Svajdler M; Pella D; Macejová Z
Isr Med Assoc J; 2015 Apr; 17(4):256-8. PubMed ID: 26040057
[No Abstract] [Full Text] [Related]
16. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
[TBL] [Abstract][Full Text] [Related]
17. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128
[TBL] [Abstract][Full Text] [Related]
18. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
[No Abstract] [Full Text] [Related]
19. [The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication].
Christensen R; Kristensen LE; Geborek P; Danneskiold-Samsøe B; Saxne T; Bliddal H
Ugeskr Laeger; 2009 Jun; 171(26):2192-4. PubMed ID: 19678436
[TBL] [Abstract][Full Text] [Related]
20. Etanercept tapering in rheumatoid arthritis.
Emery P; Hammoudeh M; Combe B
N Engl J Med; 2015 Jan; 372(5):489-90. PubMed ID: 25629751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
